Hydrazinecarboximidamide, 2-[(2E)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-2-propen-1-ylidene]-, (2E)-

Chemical Properties

Send Inquriy

Animal Model:	Male C57BL/6J wild-type (WT) and BALB/c mice^[1]
Dosage:	0, 0.1, 1 and 10 mg/kg
Administration:	Oral administration, intraperitoneal injection and intravenous injection; for 24 hours
Result:	Inhibited neutrophil and monocyte infiltration in a dose-dependent manner.

Animal Model:	Male C57BL/6J wild-type (WT) and BALB/c mice^[1]
Dosage:	25 and 50 mg/kg
Administration:	Oral administration; daily; for 8 days
Result:	Reduced all signs of arthritis measured, including clinical score (-42%), paw swelling (-87%), proportion of animals with all four paws affected (-50%), and the severity of the inflammation (-70%).